Sialidases: Therapeutic and Antiatherogenic Potential

Curr Pharm Des. 2017;23(31):4696-4701. doi: 10.2174/1381612823666170609082324.

Abstract

This review focuses on the biological role and clinical relevance of relatively poor studied enzymes known as sialidases. We describe structure and function of sialic acid, in particular as a component of gangliosides and plasma lipoproteins. Several types of sialidases are known in mammals, of which trans-sialidase is of special interest, since it is capable of removing sialic acid from low density lipoprotein (LDL) particles and transferring it to different acceptors in blood plasma. Desialylation of LDL, in turn, endows it a capacity to accumulate in the smooth muscle cells of human aortic intima, and therefore is important for atherogenesis. Moreover, sialidases appear to be involved in a variety of pathological processes, including viral infections and cancer, which makes these enzymes an attractive therapeutic target.

Keywords: LDL; Sialidase; atherosclerosis; desialylation; sialic acid; trans-sialidase.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / enzymology*
  • Humans
  • Neoplasms / drug therapy
  • Neoplasms / enzymology
  • Neoplasms / metabolism
  • Neuraminidase / antagonists & inhibitors*
  • Neuraminidase / metabolism
  • Sialic Acids / chemistry
  • Sialic Acids / metabolism

Substances

  • Antineoplastic Agents
  • Sialic Acids
  • Neuraminidase